Log in

Relevant bibliographies by topics / PDE-5 inhibitors

Contents

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers
Reports

Academic literature on the topic 'PDE-5 inhibitors'

Author: Grafiati

Published: 5 June 2025

Last updated: 2 August 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'PDE-5 inhibitors.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "PDE-5 inhibitors"

1

Sarfati, Marika, Véronique Mateo, Sylvie Baudet, et al. "Sildenafil and vardenafil, types 5 and 6 phosphodiesterase inhibitors, induce caspase-dependent apoptosis of B-chronic lymphocytic leukemia cells." Blood 101, no. 1 (2003): 265–69. http://dx.doi.org/10.1182/blood-2002-01-0075.

Full text

Abstract:

Abstract Type 4 phosphodiesterase (PDE4) inhibitors reportedly induce apoptosis in chronic lymphocytic leukemia (CLL) cells. Following clinical improvement of one previously untreated CLL patient with sildenafil therapy, we evaluated the in vitro induction of apoptosis in CLL cells by 4 PDE5/6 inhibitors, including sildenafil, vardenafil, zaprinast, and methoxyquinazoline (MQZ). After 24 hours of culture, the various PDE inhibitors differed in their ability to induce apoptosis, with zaprinast displaying no killing effect. Normal B cells isolated from control donors were totally resistant to PD

APA, Harvard, Vancouver, ISO, and other styles

2

Germain, Nöella, Elisabeth Boichot, Jean-Michel Planquois, and Vincent Lagente. "Reduced Airway Hyperresponsiveness by Phosphodiesterase 3 and 4 Inhibitors in Guinea-Pigs." Mediators of Inflammation 8, no. 3 (1999): 153–57. http://dx.doi.org/10.1080/09629359990487.

Full text

Abstract:

The aim of the present study was to compare the effects of selective phosphodiesterase (PDE) 3, 4 and 5 inhibitors on antigen-induced airway hyperresponsiveness in sensitized guinea-pigs. When the sensitized guinea-pigs were orally pre-treated with the selective PDE4 inhibitor, Ro 20-1724 (30 mg/kg), and studied 48 h after OA, a significant reduction (p<0.01) of the leftward shift of the dose-response curve to ACh was noted, whereas it was ineffective at the lower dose (10 mg/kg). Administration of the selective PDE3 inhibitor, milrinone (30 mg/kg) also elicited a significant reduction (p&l

APA, Harvard, Vancouver, ISO, and other styles

3

Ivey, F. Douglas, Lili Wang, Didem Demirbas, Christina Allain, and Charles S. Hoffman. "Development of a Fission Yeast-Based High-Throughput Screen to Identify Chemical Regulators of cAMP Phosphodiesterases." Journal of Biomolecular Screening 13, no. 1 (2007): 62–71. http://dx.doi.org/10.1177/1087057107312127.

Full text

Abstract:

Cyclic nucleotide phosphodiesterases (PDEs) comprise a superfamily of enzymes that serve as drug targets in many human diseases. There is a continuing need to identify high-specificity inhibitors that affect individual PDE families or even subtypes within a single family. The authors describe a fission yeast-based high-throughput screen to detect inhibitors of heterologously expressed adenosine 3′,5′-cyclic monophosphate (cAMP) PDEs. The utility of this system is demonstrated by the construction and characterization of strains that express mammalian PDE2A, PDE4A, PDE4B, and PDE8A and respond a

APA, Harvard, Vancouver, ISO, and other styles

4

Favot, Laure, Thérèse Keravis, Vincent Holl, Alain Bec, and Claire Lugnier. "VEGF-induced HUVEC migration and proliferation are decreased by PDE2 and PDE4 inhibitors." Thrombosis and Haemostasis 90, no. 08 (2003): 334–43. http://dx.doi.org/10.1160/th03-02-0084.

Full text

Abstract:

SummaryMigration and proliferation of endothelial cells in response to VEGF play an important role in angiogenesis associated to pathologies such as atherosclerosis, diabetes and tumor development. Elevation of cAMP in endothelial cells has been shown to inhibit growth factor-induced proliferation. Our hypothesis was that inactivation of cAMP-specific phosphodiesterases (PDEs) would inhibit angiogenesis. The purpose of this study was to evaluate the effect of PDE inhibitors on in vitro and in vivo angiogenesis, using human umbilical vein endothelial cell (HUVEC) and chick chorioallantoic membr

APA, Harvard, Vancouver, ISO, and other styles

5

Wójcik-Pszczoła, Katarzyna, Grażyna Chłoń-Rzepa, Agnieszka Jankowska та ін. "A Novel, Pan-PDE Inhibitor Exerts Anti-Fibrotic Effects in Human Lung Fibroblasts via Inhibition of TGF-β Signaling and Activation of cAMP/PKA Signaling". International Journal of Molecular Sciences 21, № 11 (2020): 4008. http://dx.doi.org/10.3390/ijms21114008.

Full text

Abstract:

Phosphodiesterase (PDE) inhibitors are currently a widespread and extensively studied group of anti-inflammatory and anti-fibrotic compounds which may find use in the treatment of numerous lung diseases, including asthma and chronic obstructive pulmonary disease. Several PDE inhibitors are currently in clinical development, and some of them, e.g., roflumilast, are already recommended for clinical use. Due to numerous reports indicating that elevated intracellular cAMP levels may contribute to the alleviation of inflammation and airway fibrosis, new and effective PDE inhibitors are constantly b

APA, Harvard, Vancouver, ISO, and other styles

6

Blanco-Rivero, Javier, and Fabiano E. Xavier. "Therapeutic Potential of Phosphodiesterase Inhibitors for Endothelial Dysfunction- Related Diseases." Current Pharmaceutical Design 26, no. 30 (2020): 3633–51. http://dx.doi.org/10.2174/1381612826666200403172736.

Full text

Abstract:

Cardiovascular diseases (CVD) are considered a major health problem worldwide, being the main cause of mortality in developing and developed countries. Endothelial dysfunction, characterized by a decline in nitric oxide production and/or bioavailability, increased oxidative stress, decreased prostacyclin levels, and a reduction of endothelium-derived hyperpolarizing factor is considered an important prognostic indicator of various CVD. Changes in cyclic nucleotides production and/ or signalling, such as guanosine 3&#039;, 5&#039;-monophosphate (cGMP) and adenosine 3&#039;, 5&#0

APA, Harvard, Vancouver, ISO, and other styles

7

Doumas, Michael, Antonios Lazaridis, Niki Katsiki, and Vasilios Athyros. "PDE-5 Inhibitors: Clinical Points." Current Drug Targets 16, no. 5 (2015): 420–26. http://dx.doi.org/10.2174/1389450115666141111111301.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Efremov, E. A. Efremov, E. V. Kasatonova Kasatonova, Ya I. Mel’nik Mel’nik, and A. A. Nikushina Nikushina. "PDE-5 inhibitors: patients’ preferences." Urologiia 3_2017 (July 18, 2017): 120–26. http://dx.doi.org/10.18565/urol.2017.3.120-126.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Kumar, Shivendra, Dr Mayank Kulshreshtha, and Sunam Saha. "Contribution of Phosphodiesterase-5 (PDE5) Inhibitors in the Various Diseases." International Journal of Science and Healthcare Research 7, no. 4 (2022): 164–72. http://dx.doi.org/10.52403/ijshr.20221023.

Full text

Abstract:

The PDE-5 inhibitors, i.e., phosphodiesterase-5 inhibitors like sildenafil, vardenafil, and tadalafil, are the most used in premature erectile dysfunction. Many literature reviews suggest that these classes of drugs are commonly used in erectile dysfunction. Many of these reviews suggest that these inhibitors (PDE-5) are used in many other diseases apart from erectile dysfunction. So, in this review, we find the main mechanism of action of PDE-5 inhibitors in different disease conditions. These inhibitors have a major role in different diseases like erectile dysfunction, memory enhancement, ca

APA, Harvard, Vancouver, ISO, and other styles

10

McCullough, Andrew R. "An Update on the PDE-5 Inhibitors (PDE-5i)." Journal of Andrology 24, S6 (2003): S52—S58. http://dx.doi.org/10.1002/j.1939-4640.2003.tb02747.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "PDE-5 inhibitors"

1

Nickum, Elisa A. "Analysis of Regulated Drugs Using Chromatographic and Spectrophotometric Techniques Coupled with Spectroscopy An Orthogonal Approach to Protecting Public Health." University of Cincinnati / OhioLINK, 2017. http://rave.ohiolink.edu/etdc/view?acc_num=ucin1504799568245931.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Santos, Filho Hilton Oliveira dos 1956. "Estudo clínico fase I de carbonato de lodenafila, um novo tipo de inibidor de fosfodiesterase 5 (PDE5), em voluntários saudáveis do sexo masculino = A phase I clinical trial of lodenafil carbonate, a new phosphodiesterase type 5 (PDE5) inhibitor, in healthy male volunteers." [s.n.], 2013. http://repositorio.unicamp.br/jspui/handle/REPOSIP/309461.

Full text

Abstract:

Orientador: Gilberto De Nucci<br>Tese (doutorado) - Universidade Estadual de Campinas, Faculdade de Ciências Médicas<br>Made available in DSpace on 2018-08-22T19:42:28Z (GMT). No. of bitstreams: 1 SantosFilho_HiltonOliveirados_D.pdf: 1622141 bytes, checksum: 5f817cf4a04ee643bdf7e261e5861691 (MD5) Previous issue date: 2013<br>Resumo: Carbonato de Lodenafila é um novo tipo de inibidor de fosfodiesterase 5 (PDE5) utilizado no tratamento da disfunção erétil. O presente estudo foi realizado para avaliar a segurança, tolerabilidade e farmacocinética do carbonato de lodenafila após a administração

APA, Harvard, Vancouver, ISO, and other styles

3

Kalsi, J. S. "The effect of soluble guanylate cyclase activators and a nitric oxide releasing PDE 5 inhibitor on cavernosal and anococcygeal smooth muscle function in conditions of nitric oxide deficiency." Thesis, University College London (University of London), 2011. http://discovery.ucl.ac.uk/1333229/.

Full text

Abstract:

Introduction: PDE5 inhibitors improve erections by potentiating nitric oxide (NO)- cyclic guanosine monophosphate system. However, long-term diabetic patients have reduced efficacy secondary to dysfunction of NO system. The aim of this thesis was to investigate in-vitro effects of a PDE5 inhibitor (sildenafil), a soluble guanylate cyclase (sGC) activator (BAY41-2272) and an NO-releasing PDE5 inhibitor (NCX-911) on urogenital smooth muscle in conditions of NO deficiency. Method: The effect of these compounds was investigated on tone and electrical field stimulation-induced nitrergic relaxation

APA, Harvard, Vancouver, ISO, and other styles

4

Capdeville, Marion-Justine. "Études des cycles biogéochimiques des contaminants organiques dits « émergents » dans les systèmes aquatiques." Thesis, Bordeaux 1, 2011. http://www.theses.fr/2011BOR14304/document.

Full text

Abstract:

Les substances pharmaceutiques font partie du groupe des contaminants émergents du fait de leur intérêt récent dans les études environnementales comparativement à des polluants étudiés depuis plus longtemps tels que les pesticides. Elles correspondent aux principes actifs des médicaments et, à ce titre, sont responsables des propriétés pharmacologiques des médicaments. Ce sont donc des molécules biologiquement actives qui peuvent agir sur les organismes vivants présents dans les écosystèmes impactés. L’origine des substances pharmaceutiques dans l’environnement est variable mais les principale

APA, Harvard, Vancouver, ISO, and other styles

5

Capdeville, Marion-Justine. "Études des cycles biogéochimiques des contaminants organiques dits « émergents » dans les systèmes aquatiques." Electronic Thesis or Diss., Bordeaux 1, 2011. http://www.theses.fr/2011BOR14304.

Full text

Abstract:

Les substances pharmaceutiques font partie du groupe des contaminants émergents du fait de leur intérêt récent dans les études environnementales comparativement à des polluants étudiés depuis plus longtemps tels que les pesticides. Elles correspondent aux principes actifs des médicaments et, à ce titre, sont responsables des propriétés pharmacologiques des médicaments. Ce sont donc des molécules biologiquement actives qui peuvent agir sur les organismes vivants présents dans les écosystèmes impactés. L’origine des substances pharmaceutiques dans l’environnement est variable mais les principale

APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "PDE-5 inhibitors"

1

Porst, Hartmut. Erectile dysfunction. Edited by David John Ralph. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199659579.003.0103.

Full text

Abstract:

Erectile dysfunction (ED) can be improved by changing certain lifestyle factors such as sedentary lifestyle, unhealthy food, nicotine and alcohol abuse, or optimal management of risk factors/concomitant diseases causing or aggravating ED such as dyslipidaemia, hypertension, diabetes mellitus, depression, BPH/LUTS, or hypogonadism.First choice in the medical therapy of ED are PDE-5 inhibitors such as sildenafil, vardenafil, and tadalafil used p.r.n, or on a daily low-dose regimen regarding tadalafil, especially in patients suffering from ED and BPH/LUTS. Yohimbine and L-arginine may be consider

APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "PDE-5 inhibitors"

1

Koka, Saisudha, and Rakesh C. Kukreja. "PDE-5 Inhibitors in Protection of Diabetic Heart." In Diabetic Cardiomyopathy. Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4614-9317-4_20.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Rokkas, Konstantinos. "Management of Erectile Dysfunction Beyond PDE-5 Inhibitors." In Erectile Dysfunction in Hypertension and Cardiovascular Disease. Springer International Publishing, 2014. http://dx.doi.org/10.1007/978-3-319-08272-1_20.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

McCullough, Andrew R. "Sexual Dysfunction After Radical Prostatectomy and the Use of PDE-5 Inhibitors." In Oral Pharmacotherapy for Male Sexual Dysfunction. Humana Press, 2005. http://dx.doi.org/10.1385/1-59259-871-4:409.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Eroglu, Imdat, Nuriye Ozdemir, and Ozan Yazici. "Immunotherapy in Brain, Head and Neck Cancer." In Immunotherapy in Human Cancers. Nobel Tip Kitabevleri, 2024. http://dx.doi.org/10.69860/nobel.9786053359388.11.

Full text

Abstract:

Besides immunotherapy, several other pathways are targeted in Head and Neck (HNC) for future treatment. HRAS, NTRK, MSI, NOTCH, and PIK3A are targetable pathways for HNC. Tipifarnib showed promising results in patients with HNC having HRAS mutation in phase 2 studies. Xevinapant, a potent oral inhibitor of the apoptosis proteins antagonist, is another novel molecule tested as a treatment option in HNC. A phase 2 trial showed that the addition of xevinapant to the CRT in locally advanced HNC results in very promising 5-yr OS benefits (53 % vs 28 %) compared to the CRT+placebo ( Multiomic studie

APA, Harvard, Vancouver, ISO, and other styles

5

Szturz, Petr, and Jan B. Vermorken. "Systemic Treatment Sequencing and Prediction of First-line Therapy Outcomes in Recurrent or Metastatic Head and Neck Cancer." In Critical Issues in Head and Neck Oncology. Springer International Publishing, 2023. http://dx.doi.org/10.1007/978-3-031-23175-9_13.

Full text

Abstract:

AbstractIn the palliative management of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who are not candidates for a complete resection or full-dose radiotherapy, systemic treatment has seen important advances over the past several decades. In general, there are six major factors impacting on the decision-making process. Four of them belong to a class of continuous functions and include overall health status (from fitness to frailty), disease burden (from high to low), pace of the disease (from fast to slow), and expression of programmed-death ligand 1 (P

APA, Harvard, Vancouver, ISO, and other styles

6

Agolti, Mariela, and Lucrecia Solari. "Review of F-18 FDG PET/CT in Evaluating Response to Immunotherapy Treatment." In Beyond Becquerel and Biology to Precision Radiomolecular Oncology: Festschrift in Honor of Richard P. Baum. Springer International Publishing, 2024. http://dx.doi.org/10.1007/978-3-031-33533-4_2.

Full text

Abstract:

AbstractIntroduction: Immunotherapy is a wide-spreading therapeutic resource in oncology. The therapy is guided to improve the patient’s immune response to cancer cells, on the basis of the concept of immune surveillance by activating both cell-mediated and humoral immunity to fight cancer. Immunomodulatory monoclonal antibody therapy utilizes preformed monoclonal antibodies directed against molecular targets to regulate T-cell activation. There are three mechanisms involved in this kind of therapy: antibodies directed against the programmed death protein 1 (PD-1)/programmed death receptor lig

APA, Harvard, Vancouver, ISO, and other styles

7

"PDE 5 Inhibitors for Erectile Dysfunction." In Contemporary Drug Synthesis. John Wiley & Sons, Inc., 2004. http://dx.doi.org/10.1002/0471686743.ch13.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Das, Anindita, Fadi N., and Rakesh C. "The Role of PDE-5 Inhibitors in Prostate Cancer." In Prostate Cancer - Diagnostic and Therapeutic Advances. InTech, 2011. http://dx.doi.org/10.5772/25380.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Becker, Richard C., and Frederick A. Spencer. "Aggrenox and Cilostazol." In Fibrinolytic and Antithrombotic Therapy. Oxford University Press, 2006. http://dx.doi.org/10.1093/oso/9780195155648.003.0015.

Full text

Abstract:

The dipyridamole component of Aggrenox and cilostazol, both phosphodiesterase inhibitors, are used predominantly in patients with peripheral vascular and cerebrovascular disease. Aggrenox is a combination platelet antagonist that includes aspirin (25 mg) and dipyridamole (200 mg extended-release preparation). It is typically taken twice daily. Aspirin’s mechanism of action has been discussed previously. Dipyridamole inhibits cyclic adenosine monophosphate (cAMP)-phosphodiesterase (PDE) and cyclic-3´, 5´- guanylate monophospate (GMP)-PDE (Bunag et al., 1964). The pharmacokinetic profile of aspi

APA, Harvard, Vancouver, ISO, and other styles

10

Reynard, John, Simon F. Brewster, Suzanne Biers, and Naomi Laura Neal. "Sexual health." In Oxford Handbook of Urology. Oxford University Press, 2019. http://dx.doi.org/10.1093/med/9780198783480.003.0013.

Full text

Abstract:

This andrology chapter covers the physiology of erection and ejaculation and expands on the evaluation and treatment of erectile dysfunction (ED), including the use of drugs (phosphodiesterase type-5 inhibitors or PDE-5I), intracavernosal injections, and insertion of penile prosthesis. The evaluation and treatment of Peyronie’s disease with Nesbitt or Lue procedure are explained. Ejaculatory dysfunction is covered, including the topics of retrograde, premature, delayed and absent ejaculation, and anorgasmia. The topical subjects of late-onset hypogonadism (LOH) and general male hypogonadism ar

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "PDE-5 inhibitors"

1

Haque, Jiyaul, Vandana Srivastava, and Ma Quraishi. "Phenylalanine Derived Zwitterion as Novel Corrosion Inhibitor for Mild Steel in 1M HCl: Electrochemical, Surface and DFT Studies." In CORROSION 2019. NACE International, 2019. https://doi.org/10.5006/c2019-12800.

Full text

Abstract:

Abstract The Phenylalanine based corrosion inhibitor 2-(3-(1-carboxy-2-phenylethyl)-1H-imidazol-3-ium-1-yl)-5-methyl-3-phenylpropanoate (IP) was synthesized by the condensation of phenylalanine, 2-oxopropanal, and formaldehyde and characterized by the FTIR and NMR spectroscopy. The corrosion inhibition performance of synthesized inhibitor was studied by electrochemical impedance spectroscopy (EIS), potentiodynamic polarization (PDP), Surface and DFT methods. The results show the studied IP is an effective inhibitor which showed the maximum inhibition efficiency of 96.08% at concentration 200pp

APA, Harvard, Vancouver, ISO, and other styles

2

Beretz, A., F. Lanza, A. Stierlé, and J.-P. Cazenave. "CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS PREVENT AGGREGATION AND SECRETION OF HUMAN PLATELETS BY RAISING CYCLIC AMP AND REDUCING CYTOPLASMIC FREE CALCIUM MOBILIZATION." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643586.

Full text

Abstract:

Drugs that raise platelet cyclic AMP (cAMP) are potent inhibitors of platelet activation. We have studied the effects of 5 inhibitors of cyclic nucleotide phosphodiesterase (PDE) of different chemical structures (quercetin, Ro 15-2041, HL-725, cilostamide and MY-5445), which are all potent inhibitors of platelet function. The concentrations that inhibit by 50 % crude cAMP-PDE activity (IC50) from human platelets are: 0.06 μM(HL-725), 0.15 μM(Ro 15-2041 ), 0.23 μM(cilostamide), 6.9 μM(MY-5445) and 44.4 μM(quercetin). We measured on the same preparation of washed human platelets loaded with quin

APA, Harvard, Vancouver, ISO, and other styles

3

Matusov, Y., and K. K. Wei. "Inadequate Diagnostic Testing for Patients Started on PDE-5 Inhibitors for Pulmonary Hypertension." In American Thoracic Society 2020 International Conference, May 15-20, 2020 - Philadelphia, PA. American Thoracic Society, 2020. http://dx.doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a3825.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Gray, S. J., and S. Heptinstall. "INTERACTIONS BETWEEn PGE2 AND INHIBITORS OF PLATELET AGGREGATION THAT ACT THROUGH cAMP." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643582.

Full text

Abstract:

PGE2 has a biphasic effect on platelet aggregation with low concentrations of the prostaglandin potentiating aggregation and high concentrations inhibiting it. In this investigation we have studied the interaction of PGE2 with agents that inhibit platelet aggregation through an effect on cAMP. The agents chosen raise the level of cAMP in platelets by different mechanisms: PGI2, PGD9 and adenosine combine with specific surface-located receptors and stimulate adenylate cyclase (AC) via a guanine nucleotide-binding protein (GNBP), forskolin stimulates AC directly, and AH-P 719 and DN 9693 inhibit

APA, Harvard, Vancouver, ISO, and other styles

5

Laddha, Sachin, Sandeep Waghulde, Omprakash Tanwar, Chandrabose Karthikeyan, and Mukesh Bhaisare. "A QSAR analysis of some amino substituted Pyrido[3,2-b]pyrazinones as potent and selective PDE-5 inhibitors." In The 14th International Electronic Conference on Synthetic Organic Chemistry. MDPI, 2010. http://dx.doi.org/10.3390/ecsoc-14-00445.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Laddha, Sachin, Sandeep Waghulde, Omprakash Tanwar, Chandrabose Karthikeyan, and Mukesh Bhaisare. "A QSAR analysis of some amino substituted Pyrido[3,2-b]pyrazinones as potent and selective PDE-5 inhibitors." In The 14th International Electronic Conference on Synthetic Organic Chemistry. MDPI, 2010. http://dx.doi.org/10.3390/ecsoc-14-00465.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Hoeper, Marius, Raymond Benza, Gerald Simonneau, et al. "Rationale and study design of the RESPITE trial: Riociguat clinical effects studied in pulmonary arterial hypertension (PAH) patients with insufficient treatment response to PDE-5 inhibitors (PDE-5i)." In Annual Congress 2015. European Respiratory Society, 2015. http://dx.doi.org/10.1183/13993003.congress-2015.pa2110.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Dardi, F., M. Palazzini, E. Zuffa, et al. "Short Term Effect of Selexipag in Comparison to Prostacyclin Analogues in Pulmonary Arterial Hypertension Patients Started on Double-Combination Therapy with ERA and PDE-5 Inhibitors." In American Thoracic Society 2020 International Conference, May 15-20, 2020 - Philadelphia, PA. American Thoracic Society, 2020. http://dx.doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a3826.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Kandolf Sekulović, Lidija. "TOXICITIES OF TARGETED THERAPY AND IMMUNE-RELATED ADVERSE DRUG REACTIONS OF IMMUNOTHERAPY IN THE TREATMENT OF METASTATIC MELANOMA." In Okrugli sto s međunarodnim učešćem "Melanom". Akademija nauka i umjetnosti Bosne i Hercegovine, 2018. http://dx.doi.org/10.5644/pi2019.180.04.

Full text

Abstract:

Targeted therapy and immunotherapy changed the treatment landscape for metastatic melanoma, which is chemotherapy resistant cancer. In pre-innovation era, the overall survival of patients with metastatic melanoma was 6 months, while today 5-year overall survival rate of 34% (and 50% in good prognostic groups) is evident. However, both treatments have their side effects, and cutaneous are the most frequent. Treating physicians in oncology centres, but also primary care specialists, need to be aware of their spectrum which differs for each class of drug: BRAF inhibitors, MEK inhibitors and immun

APA, Harvard, Vancouver, ISO, and other styles

10

Cvetković, Aleksandar, Mihajlović Petrović, Žaklina Tasić, Milan Radovanović, Ana Simonović, and Vladan Nedelkovski. "Influence of organic compound structure on brass corrosion inhibition efficiency." In Proceedings of XVI International Mineral Processing and Recycling Conference, Belgrade, 28-30.05.2025. University of Belgrade, Technical Faculty, Bor, 2024. https://doi.org/10.5937/imprc25497c.

Full text

Abstract:

In this study the influence of organic compounds with different structures on the inhibition of brass corrosion in sodium chloride solutions of 0.9%, 2% and 3.5% is investigated. The experimental work includes the evaluation of the inhibition efficiency of 2-mercapto-1-methylimidazole (MMI), 2-amino-5-ethyl1,3,4-thiadiazole (AETDA) and N-acetyl-L-leucine at various concentrations using electrochemical methods, including open circuit potential (OCP), cyclic voltammetry (CV), and potentiodynamic measurements (PD). The results show that all tested inhibitors reduce the corrosion currents and pote

APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "PDE-5 inhibitors"

1

Chejanovsky, Nor, and Bruce A. Webb. Potentiation of Pest Control by Insect Immunosuppression. United States Department of Agriculture, 2010. http://dx.doi.org/10.32747/2010.7592113.bard.

Full text

Abstract:

The restricted host range of many baculoviruses, highly pathogenic to Lepidoptera and non-pathogenic to mammals, limits their use to single or few closely related Lepidopteran species and is an obstacle to extending their implementation for pest control. The insect immune response is a major determinant of the ability of an insect pathogen to efficiently multiply and propagate. We have developed an original model system to study the Lepidopteran antiviral immune response based on Spodoptera littoralis resistance to AcMNPV (Autographa californica multiple nucleopolyhedrovirus) infection and the

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!